Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients

• Published in: Canadian Medical Association journal (CMAJ) Vol. 173; no. 2; pp. 160 - 164
• Main Authors: Braitstein, Paula, Yip, Benita, Montessori, Valentina, Moore, David, Montaner, Julio S G, Hogg, Robert S
• Format: Journal Article
• Language: English
• Published: Canada CMA Impact Inc 19.07.2005; CMA Impact, Inc; Canadian Medical Association
• Subjects: Adult; Anti-Retroviral Agents - therapeutic use; Antiviral agents; Care and treatment; Complications and side effects; Cross-Sectional Studies; Drug therapy; Drug use; Female; Hepacivirus - pathogenicity; Hepatitis; Hepatitis C; Hepatitis C - complications; Hepatitis C - mortality; HIV; HIV Infections - complications; HIV Infections - drug therapy; HIV Infections - mortality; HIV patients; Human immunodeficiency virus; Humans; Male; Medical treatment; Mortality; Patients; Prognosis; Risk Factors; Serologic Tests; Viral Load; Canada
• ISSN: 0820-3946; 1488-2329
• DOI: 10.1503/cmaj.045202

We examined the effect of hepatitis C virus (HCV) seropositivity on risk of death among people receiving their first antiretroviral treatment (ART) for HIV infection. In British Columbia, the HIV/ AIDS Drug Treatment Program is the only source of free ART. Patients who initiated a triple-drug ART regimen between July 31, 1996, and July 31, 2000, were included if they were ART-naive and had baseline HCV serological data. Outcomes of interest for survival analysis were deaths from natural and HIV-related causes, with a data cutoff of June 30, 2003. Of 1186 eligible subjects, 606 (51%) were HCV positive and 580, negative. Fewer HCV-positive people were male (78% v. 93%, p < 0.001) and had an AIDS diagnosis at baseline (11% v. 15%, p = 0.028). Their CD4 fraction was significantly higher at baseline (19% v. 16% of T lymphocytes, p < 0.001) but their absolute CD4 counts, log HIV viral load and the type of ART initiated were similar to those of HCV negative people. Of 163 deaths (from natural causes only) during the study period, 118 (19%) were in HCV positive and 45 (8%) in HCV negative patients (p < 0.001); of the 114 deaths attributed to HIV infection, these proportions were 79 (13%) versus 35 (6%; p < 0.001). After adjustment for potential confounders, HCV seropositivity remained predictive of death (adjusted hazard ratio [HR] 2.20, 95% confidence interval [CI] 1.50- 3.21, p < 0.001), especially HIV-related death (adjusted HR 1.75, 95% CI 1.13- 2.72, p = 0.012). In this population-based HIV treatment program, we found HCV seropositivity to be an independent predictor of mortality, especially death related to HIV infection.